Zsuzsanna Nagy
Overview
Explore the profile of Zsuzsanna Nagy including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
81
Citations
741
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Dias R, Brock K, Hu K, Gupta R, Martin U, Peet A, et al.
BMJ Open
. 2025 Feb;
15(2):e091495.
PMID: 40010822
Introduction: Wolfram syndrome (Spectrum Disorder) is an ultra-rare monogenic form of progressive neurodegeneration and diabetes mellitus. In common with most rare diseases, there are no therapies to slow or stop...
2.
Nagy Z, Obeidat M, Mate V, Nagy R, Szanto E, Veres D, et al.
JAMA Pediatr
. 2025 Jan;
179(2):145-154.
PMID: 39786414
Importance: Intraventricular hemorrhage (IVH) has been described to typically occur during the early hours of life (HOL); however, the exact time of onset is still unknown. Objective: To investigate the...
3.
Srinivasan V, Homer V, Barton D, Clutterbuck-James A, Jenkins S, Potter C, et al.
PLoS One
. 2024 Jul;
19(7):e0291285.
PMID: 38990927
Background: Amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig´s disease, is a rare neurological condition and is the most common motor neurone disease. It is a fatal disease with...
4.
Unger V, Gasparics A, Nagy Z, Hernadfoi M, Nagy R, Walter A, et al.
Am J Obstet Gynecol
. 2024 Jun;
231(6):589-598.e21.
PMID: 38908650
Objective: To investigate the association between actual and planned modes of delivery, neonatal mortality, and short-term outcomes among preterm pregnancies ≤32 weeks of gestation. Data Sources: A systematic literature search...
5.
Grinshpun A, Russo D, Ma W, Verma A, Hermida-Prado F, Sherman S, et al.
NPJ Breast Cancer
. 2024 Jun;
10(1):42.
PMID: 38851818
The ESR1 ligand binding domain activating mutations are the most prevalent genetic mechanism of acquired endocrine resistance in metastatic hormone receptor-positive breast cancer. These mutations confer endocrine resistance that remains...
6.
Karvaly G, Vincze I, Neely M, Zatroch I, Nagy Z, Kocsis I, et al.
Pharmaceutics
. 2024 Mar;
16(3).
PMID: 38543252
Population pharmacokinetic (pop-PK) models constructed for model-informed precision dosing often have limited utility due to the low number of patients recruited. To augment such models, an approach is presented for...
7.
Guarducci C, Nardone A, Russo D, Nagy Z, Heraud C, Grinshpun A, et al.
Clin Cancer Res
. 2024 Feb;
30(9):1889-1905.
PMID: 38381406
Purpose: Resistance to endocrine therapy (ET) and CDK4/6 inhibitors (CDK4/6i) is a clinical challenge in estrogen receptor (ER)-positive (ER+) breast cancer. Cyclin-dependent kinase 7 (CDK7) is a candidate target in...
8.
Barath L, Bakucs Z, Zsofia Benedek , Ferto I, Nagy Z, Vigh E, et al.
Sci Total Environ
. 2023 Oct;
906:167518.
PMID: 37813258
The literature on the effectiveness of Agri-Environmental Schemes focuses mainly on the environmental effects; only a few studies have focused on economic aspects. The number of papers that address ecological...
9.
Hermida-Prado F, Xie Y, Sherman S, Nagy Z, Russo D, Akhshi T, et al.
Cancer Res
. 2023 Jul;
83(19):3284-3304.
PMID: 37450351
Significance: Adding SMAC mimetics to endocrine therapy enhances tumor regression in a cell autonomous manner while increasing tumor immunogenicity, indicating that this combination could be an effective treatment for HR+...
10.
Nagy Z, Herbison A, Kwakowsky A, Kovacs G, Barabas K
Front Endocrinol (Lausanne)
. 2023 May;
14:1192671.
PMID: 37139335
No abstract available.